EBITDA stood at Rs 121.3 crore in Q4 FY26, up 67.2% compared with Rs 72.6 crore in Q4 FY25. EBITDA margin expanded to 23.6% in Q4 FY26 as against 20.3% in Q4 FY25.

In dollar terms, revenue rose 35% to $56 million in Q4 FY26 from $41 million in Q4 FY25. Approximately 98% of the company's revenue is denominated in US dollars.

On full year basis, the company’s consolidated net profit jumped 83.63% to Rs 246.73 crore in FY26 compared with Rs 134.36 crore in FY25. Revenue from operations climbed 36.57% to Rs 1,753.95 crore in FY26 from Rs 1,284.27 crore posted in FY25.

Meanwhile, the company’s board recommended a dividend of Rs 1.50 per equity share of the face value of Re 1 each fully paid up, for the financial year ended March 31, 2026.

Rubicon Research is a pharmaceutical formulations company focused on innovation-led research and development, with a growing portfolio of specialty products and drug–device combination offerings aimed at regulated markets.